Evidence map›Paper›PMID 36430833›Full record

ArticleInternational journal of molecular sciences2022

Antiandrogenic Effects of a Polyphenol in

Yudai Kudo, Satoshi Endo, Masatoshi Tanio, Tomofumi Saka, Rin Himura, Naohito Abe, Mitsumi Takeda, Eiji Yamaguchi, Yuta Yoshino, Yuki Arai and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Antioxidants (Basel, Switzerland) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Yudai KudoLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Satoshi EndoLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.ORCID 0000-0003-0578-9672
Masatoshi TanioLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Tomofumi SakaLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Rin HimuraLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Naohito AbeLaboratory of Pharmacognosy, Gifu Pharmaceutical University, Gifu 501-1196, Japan.ORCID 0000-0002-2757-3736
Mitsumi TakedaLaboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Eiji YamaguchiLaboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Yuta YoshinoLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Yuki AraiUniversal Corporation Co., Ltd., Gifu 502-0931, Japan.
Hirohito KashiwagiLaboratory of Pharmacognosy, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Masayoshi OyamaLaboratory of Pharmacognosy, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Akichika ItohLaboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.ORCID 0000-0002-0072-2981
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-3306-4858
Naohiro FujimotoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Akira IkariLaboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan.ORCID 0000-0003-2696-0897
Gifu Pharmaceutical University · JPKyushu University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

Japan Agency for Medical Research and Development JP20lm0203002Japan Society for the Promotion of Science 17K11151Suzuken (Japan) Memorial Foundation
6 · The paper itself

Abstract

Prostate cancer (PC) represents the most common cancer disease in men. Since high levels of androgens increase the risk of PC, androgen deprivation therapy is the primary treatment; however this leads to castration-resistant PC (CRPC) with a poor prognosis. The progression to CRPC involves ectopic androgen production in the adrenal glands and abnormal activation of androgen signaling due to mutations and/or amplification of the androgen receptor (AR) as well as activation of androgen-independent proliferative pathways. Recent studies have shown that adrenal-derived 11-oxygenated androgens (11-ketotestosterone and 11-ketodihydrotestosterone) with potencies equivalent to those of traditional androgens (testosterone and dihydrotestosterone) are biomarkers of CRPC. Additionally, dehydrogenase/reductase SDR family member 11 (DHRS11) has been reported to be a 17β-hydroxysteroid dehydrogenase that catalyzes the production of the 11-oxygenated and traditional androgens. This study was conducted to evaluate the pathophysiological roles of DHRS11 in PC using three LNCaP, C4-2 and 22Rv1 cell lines. DHRS11 silencing and inhibition resulted in suppression of the androgen-induced expression of AR downstream genes and decreases in the expression of nuclear AR and the proliferation marker Ki67, suggesting that DHRS11 is involved in androgen-dependent PC cell proliferation. We found that 5,7-dihydroxy-8-methyl-2-[2-(4-hydroxyphenyl)ethenyl]-4

Indexed as

Carex PlantProstatic Neoplasms, Castration-Resistant17-Hydroxysteroid DehydrogenasesAndrogen AntagonistsAndrogensCell Line, TumorDown-RegulationHumansMalePolyphenolsReceptors, Androgen17-Hydroxysteroid DehydrogenasesAndrogen AntagonistsAndrogensDHRS11 protein, humanPolyphenolsReceptors, Androgenandrogen receptorCarex kobomugiDHRS11polyphenolprostate cancer

Identifiers

PMID36430833
PMCPMC9696374
OpenAlexW4309719936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.